Access DB# 146266

SEARCH REQUEST FORM

RECEIVED
FEB 25 2005

Scientific and Technical Information Center

Requester's Full Name: Sabrina Wood (STIC) Examiner #: 7414 Date: 2/24/05

Art Unit: 1616 Phone Number 30 20622 Serial Number: 10/779,331

Mail Box and Bldg/Room Location: 2 Results Format Preferred (circle): PAPER DISK E-MAIL

4C70 - Rm - 4A45

If more than one search is submitted, please prioritize searches in order of need. MEJ

****

Please provide a detailed statement of the search topic, and describe as specifically as possible the subject matter to be searched. Include the elected species or structures, keywords, synonyms, acronyms, and registry numbers, and combine with the concept or utility of the invention. Define any terms that may have a special meaning. Give examples or relevant citations, authors, etc, if known. Please attach a copy of the cover sheet, pertinent claims, and abstract.

Title of invention: AGOSTON et al.

Inventors (please provide full names): Anti-Angiogenic agents

Earliest Priority Filing Date: 2/8/2001

**For Sequence Searches Only* Please include all pertinent information (parent, child, divisional, or issued patent numbers) along with the appropriate serial number.*

Please search for the compds of formula I.

Please not a proviso, in the last line of Cl 1.

Please see attached sheet

Thank you

****

STAFF USE ONLY	Type of Search		Vendors and cost where applicable	
Searcher:	NA Sequence (#)		STN	327.91
Searcher Phone #:	AA Sequence (#)		Dialog	
Searcher Location:	Structure (#)	3	Questel/Orbit	
Date Searcher Picked Up:	Bibliographic		Dr.Link	
Date Completed: 3/7	Litigation		Lexis/Nexis	
Searcher Prep & Review Time: 20	Fulltext		Sequence Systems	
Clerical Prep Time:	Patent Family		WWW/Internet	
Online Time 20	Other		Other (specify)	

PTO-1590 (8-01)

=> d que 13
L1 STR



N~N~N
@22 23 24

C≡C~G2
@25 26 27

Ak @

CH=CH~G2
@28 29 30

Ak~CH=CH2
@31 32 33

Ak~Cb~CH=CH2
@34 35 36 37

Cb~Ak~CH=CH2
@38 39 40 41

C≡CH
@42 43

Ak~G3
@44 45

Ak~Cb~G3
@46 47 48

Cb~Ak~G3
@49 50 51

Ak~Cb
@53 54

Cb~Ak
@55 56

CH~G5
@57 58

G5~C~G5
59 @60 61

Cy @62

Page 1-A

52

Page 1-B
VAR G1=22/25/28/31/34/38/42/44/46/49
VAR G2=52/53/55
VAR G3=OH/NH2/CL/BR/I/F/CF3
VAR G4=57/60
VAR G5=AK/62
NODE ATTRIBUTES:
CONNECT IS E2 RC AT 31
CONNECT IS E2 RC AT 34
CONNECT IS E2 RC AT 35
CONNECT IS E2 RC AT 38
CONNECT IS E2 RC AT 39
CONNECT IS E2 RC AT 44
CONNECT IS E2 RC AT 46
CONNECT IS E2 RC AT 47
CONNECT IS E2 RC AT 49
CONNECT IS E2 RC AT 50
CONNECT IS E1 RC AT 52
CONNECT IS E2 RC AT 53
CONNECT IS E1 RC AT 54
CONNECT IS E2 RC AT 55
CONNECT IS E1 RC AT 56
DEFAULT MLEVEL IS ATOM

```
GGCAT    IS UNS  AT  35
GGCAT    IS UNS  AT  38
GGCAT    IS UNS  AT  47
GGCAT    IS UNS  AT  49
GGCAT    IS UNS  AT  54
GGCAT    IS UNS  AT  55
GGCAT    IS UNS  AT  62
DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:
RING(S) ARE ISOLATED OR EMBEDDED
NUMBER OF NODES IS  62

STEREO ATTRIBUTES: NONE
L3              0 SEA FILE=REGISTRY SSS FUL L1
```

=> d que 14
L1 STR



N~N~N @22 23 24

C≡C~G2 @25 26 27

Ak @

CH=CH~G2 @28 29 30

Ak~CH=CH2 @31 32 33

Ak~Cb~CH=CH2 @34 35 36 37

Cb~Ak~CH=CH2 @38 39 40 41

C≡CH @42 43

Ak~G3 @44 45

Ak~Cb~G3 @46 47 48

Cb~Ak~G3 @49 50 51

Ak~Cb @53 54

Cb~Ak @55 56

CH~G5 @57 58

G5~C~G5 59 @60 61

Cy @62

Page 1-A

52

Page 1-B
VAR G1=22/25/28/31/34/38/42/44/46/49
VAR G2=52/53/55
VAR G3=OH/NH2/CL/BR/I/F/CF3
VAR G4=57/60
VAR G5=AK/62
NODE ATTRIBUTES:
CONNECT IS E2 RC AT 31
CONNECT IS E2 RC AT 34
CONNECT IS E2 RC AT 35
CONNECT IS E2 RC AT 38
CONNECT IS E2 RC AT 39
CONNECT IS E2 RC AT 44
CONNECT IS E2 RC AT 46
CONNECT IS E2 RC AT 47
CONNECT IS E2 RC AT 49
CONNECT IS E2 RC AT 50
CONNECT IS E1 RC AT 52
CONNECT IS E2 RC AT 53
CONNECT IS E1 RC AT 54
CONNECT IS E2 RC AT 55
CONNECT IS E1 RC AT 56
DEFAULT MLEVEL IS ATOM

```
GGCAT    IS UNS  AT  35
GGCAT    IS UNS  AT  38
GGCAT    IS UNS  AT  47
GGCAT    IS UNS  AT  49
GGCAT    IS UNS  AT  54
GGCAT    IS UNS  AT  55
GGCAT    IS UNS  AT  62
DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:
RING(S) ARE ISOLATED OR EMBEDDED
NUMBER OF NODES IS  62

STEREO ATTRIBUTES: NONE
L4              0 SEA FILE=BEILSTEIN SSS FUL L1
```

=> d que
L1 STR



N~N~N @22 23 24

C≡C~G2 @25 26 27

Ak @

CH=CH~G2 @28 29 30

Ak~CH=CH2 @31 32 33

Ak~Cb~CH=CH2 @34 35 36 37

Cb~Ak~CH=CH2 @38 39 40 41

C≡CH @42 43

Ak~G3 @44 45

Ak~Cb~G3 @46 47 48

Cb~Ak~G3 @49 50 51

Ak~Cb @53 54

Cb~Ak @55 56

CH~G5 @57 58

G5~C~G5 59 @60 61

Cy @62

Page 1-A

52

Page 1-B
VAR G1=22/25/28/31/34/38/42/44/46/49
VAR G2=52/53/55
VAR G3=OH/NH2/CL/BR/I/F/CF3
VAR G4=57/60
VAR G5=AK/62
NODE ATTRIBUTES:
CONNECT IS E2 RC AT 31
CONNECT IS E2 RC AT 34
CONNECT IS E2 RC AT 35
CONNECT IS E2 RC AT 38
CONNECT IS E2 RC AT 39
CONNECT IS E2 RC AT 44
CONNECT IS E2 RC AT 46
CONNECT IS E2 RC AT 47
CONNECT IS E2 RC AT 49
CONNECT IS E2 RC AT 50
CONNECT IS E1 RC AT 52
CONNECT IS E2 RC AT 53
CONNECT IS E1 RC AT 54
CONNECT IS E2 RC AT 55
CONNECT IS E1 RC AT 56
DEFAULT MLEVEL IS ATOM

```
GGCAT    IS UNS  AT  35
GGCAT    IS UNS  AT  38
GGCAT    IS UNS  AT  47
GGCAT    IS UNS  AT  49
GGCAT    IS UNS  AT  54
GGCAT    IS UNS  AT  55
GGCAT    IS UNS  AT  62
DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:
RING(S) ARE ISOLATED OR EMBEDDED
NUMBER OF NODES IS  62

STEREO ATTRIBUTES: NONE
L6              6 SEA FILE=MARPAT SSS FUL L1
L7              4 SEA FILE=MARPAT ABB=ON  PLU=ON  L6/COM

=> d l7 ibib abs qhit 1-4

L7   ANSWER 1 OF 4  MARPAT  COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER:         137:279370  MARPAT
TITLE:                    Preparation of 2-methoxyestradiol derivatives as
                          antiangiogenic agents
INVENTOR(S):              Agoston, Gregory E.; Pribluda, Victor; Treston,
                          Anthony M.; Green, Shawn J.
PATENT ASSIGNEE(S):       USA
SOURCE:                   U.S. Pat. Appl. Publ., 15 pp.
                          CODEN: USXXCO
DOCUMENT TYPE:            Patent
LANGUAGE:                 English
FAMILY ACC. NUM. COUNT:   1
PATENT INFORMATION:

     PATENT NO.        KIND  DATE          APPLICATION NO.  DATE
     ----------------  ----  --------      ---------------  --------
     US 2002147183      A1   20021010      US 2001-779331   20010208
PRIORITY APPLN. INFO.:                     US 2001-779331   20010208
OTHER SOURCE(S):          CASREACT 137:279370
GI
```



I



II

AB Derivs. of 2-methoxyestradiol of formula I [R1, R4 = H, halo, CN, alkyl, OH, CH2OH, NH2, etc.; R2 = N3, CN, alkynyl, alkenyl, alkoxy, etc.; R3 = H, OH, hydroxyalkyl, etc.; R5 = H, oxo, OH, NOH, etc.; R6, R7 = H, alkyl, alkenyl, alkynyl, etc.; R8 = OH, oxo, NOH, etc.] are prepared for the treatment of mammalian disease characterized by undesirable angiogenesis. Thus, II was prepared from 2-methoxyestradiol, and had IC50 of <0.5 μM against MDA-MB-231 human breast carcinoma cells.

MSTR 1



G2 = N3
G7 = OH
G8 = 53

HC—G13
53

G13 = OH
G14 = Et
G21 = 144

HC—G22
144

MPL: claim 1

L7 ANSWER 2 OF 4 MARPAT COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 137:47357 MARPAT
TITLE: Preparation of 2-methoxyestradiol derivatives as antiangiogenic agents
INVENTOR(S): Agoston, Gregory E.; Shah, Jamshed H.; Hunsucker, Kimberly A.; Pribluda, Victor S.; Lavallee, Theresa M.; Green, Shawn J.; Herbstritt, Christopher J.; Zhan, Xiaoguo H.; Treston, Anthony M.
PATENT ASSIGNEE(S): USA
SOURCE: U.S. Pat. Appl. Publ., 37 pp., Cont.-in-part of U. S. Ser. No. 933,894.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2002082433	A1	20020627	US 2001-939208	20010824
PRIORITY APPLN. INFO.:			US 2000-641327	20000818
			US 2000-253385P	20001127
			US 2000-255302P	20001213
			US 2001-278250P	20010323
			US 2001-933894	20010821

GI



I



II

AB 2-Methoxyestradiol derivs. of formula I [R1, R4 = H, halo, CN, alkyl, OH, NH2, etc.; R2 = N3, CN, OMe, alkenyl, alkynyl, alkoxy, NH2, etc.; R3 = OH, OAc; R5 = alkyl, alkenyl, (di)alkylamino, OH, alkylene, etc.; R6, R7 = H, alkyl, alkenyl, alkynyl, halo, etc.] are prepared for treating mammalian disease characterized by undesirable angiogenesis. Thus, II was prepared from 2-methoxyestradiol and propyltriphenylphosphonium bromide. The IC50 of II against MDA-MB-231 breast tumor cells was 51.31 μM.

MSTR 1



G2 = N3
G7 = OH
G8 = 46

G11–C(46)—OH

G14 = Et
MPL: claim 1

NTE: additional double bond formation also claimed

L7 ANSWER 3 OF 4 MARPAT COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 137:6309 MARPAT
TITLE: Preparation of 2-methoxyestradiol analogs as antiangiogenic agents
INVENTOR(S): Agoston, Gregory; Shah, Jamshed H.; Hunsucker, Kimberly A.; Pribluda, Victor; Lavallee, Theresa M.; Green, Shawn J.; Herbstritt, Christopher J.; Zhan, Xiaoguo H.; Treston, Anthony
PATENT ASSIGNEE(S): Entremed, Inc., USA
SOURCE: PCT Int. Appl., 86 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002042319	A2	20020530	WO 2001-US26490	20010824
WO 2002042319	A3	20030313		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2430100	AA	20020530	CA 2001-2430100	20010824
AU 2001088386	A5	20020603	AU 2001-88386	20010824
EP 1343803	A2	20030917	EP 2001-968112	20010824
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
JP 2004537499	T2	20041216	JP 2002-544452	20010824
PRIORITY APPLN. INFO.:			US 2000-253385P	20001127
			US 2000-255302P	20001213
			US 2001-278250P	20010323
			US 2001-933894	20010821
			WO 2001-US26490	20010824

GI



I



II

AB 2-Methoxyestradiol analogs, such as I [R1, R3 = H, halo, CN, alkyl, OH, CH2OH, NH2, alkylamino; R2 = N3, CN, C.tplbond.CR, C=CHR, C.tplbond.CH, OR, amino; R = H, alkyl; Z = COH, COAc; dashed bond = single bond or double bond; R6 = H, OH, O, oxime, amino, alkyl, alkenyl; R4, R5 = H, alkyl, alkenyl, alkynyl], were prepared for treating mammalian disease characterized by undesirable angiogenesis. Thus, 2-methoxyestradiol analog II was prepared by the reaction of methyltriphenylphosphonium bromide and 2-methoxyestrone. In vitro evaluation against MDA-MB-231 breast tumor cells and HUVEC endothelial cells, II showed IC50 0.24±0 and 0.19±0.19 resp.

MSTR 1



G2 = N3
G7 = OH
G8 = 46



G14 = Et
MPL: claim 1
NTE: additional double bond formation also claimed

L7 ANSWER 4 OF 4 MARPAT COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 134:295993 MARPAT
TITLE: Estradiol conjugates and their therapeutic applications
INVENTOR(S): Stewart, Alastair George; McAllister, David James; Collis, Maree Patricia; Robertson, Alan Duncan

PATENT ASSIGNEE(S): University of Melbourne, Australia
SOURCE: PCT Int. Appl., 57 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001027132	A1	20010419	WO 2000-AU1244	20001013
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
CA 2385096	AA	20010419	CA 2000-2385096	20001013
EP 1226154	A1	20020731	EP 2000-969105	20001013
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL				
JP 2003511461	T2	20030325	JP 2001-530350	20001013
ZA 2002002622	A	20030304	ZA 2002-2622	20020404
PRIORITY APPLN. INFO.:			AU 1999-3425	19991014
			WO 2000-AU1244	20001013

GI



I



II

AB The invention discloses the preparation of conjugated prodrug of estradiol compound I (R1-R4 = H, OH, halo, alkyl, alkenyl, alkynyl, cycloalkyl, amino, aryl, keto, hydrazono, oximino, carbohydrate, peptide, etc.; m,n,p,q = 0-3), a pharmaceutically acceptable salt or in vivo hydrolyzable ester, amide carbonate or carbamate thereof, in the treatment of conditions associated with enhanced angiogenesis or accelerated cell division, such as cancer, and inflammatory conditions such as asthma and rheumatoid arthritis and hyperproliferative skin disorders including psoriasis. Thus, II [R1 = OMe, R2 = H (III)] was prepared via multi-step reaction sequence starting from β-estradiol II (R1-R2 = H). In human airway fibroblasts thrombin-stimulated increases in cell number were reduced to 12 ± 8% of the control response by III.

MSTR 1



G1 = OH / alkylcarbonyl<(1-5)> / Me
G4 = 33

HC——G1
33

G7 = OH / acyl
MPL: claim 10
NTE: or derivatives, pharmaceutically acceptable salts, or in vivo hydrolyzable esters, amides, carbonates, or carbamates
NTE: substitution is restricted
NTE: also incorporates claim 32, formulas IV, V, and VI

REFERENCE COUNT: 12 THERE ARE 12 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT